Re: Farmas USA
Re: Farmas USA
CELG
Por el Bastardo:
Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook
I hesitate to call any single earnings report a do-or-die event, but for troubled Celgene ( CELG), Friday’s first-quarter financial update comes pretty close.
Y hasta aquí puedo leer. (Chiste ochentero). Si alguien tiene acceso, que copipegue.
https://www.statnews.com/2018/04/30/celgene-beaten-down-stock/
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
SGYP
Synergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene
Pressure is growing on Synergy management to deliver results before the annual meeting.
A group of shareholders owning 4.7 million shares in the company are seeking help from activists to gain a seat on the Board.
Proxies have arrived and investors are likely to vote against executive compensation increases and a 100 million share increase.
A change in control could be the scenario that most investors could be looking for.
Annual 10-K shows the company continues to consider dilution. There's still hope Troy Hamilton, new CEO of the company will deliver good news.
Re: Farmas USA
ACAD 2h
Triangulo ascendente , vamosss trata de arrancarlooooooo